Based on our observations, gemcitabine may sensitize NPC cells to radiation by decreasing the expression of YTHDC2, which presents a possible explanation of the efficacy of gemcitabine treatment in recurrent or metastatic NPC (60, 61), and implies that YTHDC2 might be a promising therapeutic target for recurrent NPC. Here, YTHDC2 is linked to nasopharyngeal carcinoma.